Introduction
Primary liver cancer hepatocellular cancer (HCC) is among the leading reasons for cancer-related death worldwide with increasing occurrence and death.1 Currently, scientific medical diagnosis of HCC depends greatly on imaging with contrast-enhanced CT or MRI angiography to spot a signature vascular circulation pattern.2 Yet, some main liver cancer do disappoint the “typical” vascular circulation pattern.3 A considerable constraint of these standard size-based or flow-based imaging measurements is that they did not identify biological element(s) of liver cancer and are, for that reason, in some cases supplemented by biopsies for subsequent histopathology analysis. Positron Emission Tomography (FAMILY PET) uses molecular and cellular info if a suitable animal imaging biomarker exists. The medically utilized animal radiotracer, 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) illustrates increased cellular glucose metabolic process and has actually significantly affected client management with a big range of cancers. However, we and others found that FDG has specific constraints for imaging main liver cancers such as HCC due to a fairly lower FDG uptake causing high false-negative rate.4 Many other animal ligands generally display a high background uptake in the liver, which can disrupt the detection of liver cancer.
The brief peptide ZD2 (Thr-Val-Arg-Thr-Ser-Ala-Asp) particularly binds to the extra-domain B fibronectin (EDB-FN, revealed by FN1 gene),5 and was at first established for imaging prostate,6 breast7 and pancreatic cancers.8 We examined this unique brief peptide for radiolabeling with Gallium-68 (68Ga) through 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) chelator into ZD2-(68Ga-NOTA), for animal imaging of HCC. EDB-FN being an oncofetal isoform of fibronectin is plentiful in the extracellular matrix (ECM) and perivascular space of different aggressive cancers, however missing in typical tissues.9,10 Fibronectin, including its oncofetal subtype EDB-FN, is a hall marker of epithelial-to-mesenchymal shift (EMERGENCY MEDICAL TECHNICIAN), a procedure related to drug resistance and metastatic intrusion in aggressive cancers.11–14 High EDB-FN expression in main cancers is associated with a high occurrence of transition and poor general survival of clients identified with pancreatic, prostate, breast, ovarian, and head and neck cancer.15–19 Clinical proof has actually shown that oncofetal fibronectin (FN1) is extremely revealed in intrusive cancers.20–26 The Cancer Genome Atlas (TCGA) information validated the high expression of EDB-FN in human HCC, which is inversely related to client survival.
We checked ZD2-(68Ga-NOTA) for quantitative animal imaging of deadly liver cancer with an animal design of scientific importance, the naturally taking place HCC in woodchucks. The animal design (eastern woodchuck, Marmota monax) establishes HCC after persistent viral liver disease infection when it harbors a DNA infection – the woodchuck liver disease infection (WHV),27 a family member Hepadnaviridae, of which human liver disease B infection (HBV) is the model. Analogous to HBV, WHV contaminates woodchuck liver to trigger intense and persistent liver disease, causing the advancement of HCC within 2–4 years of life. We have actually developed the worth of this animal design for making it possible for the advancement and characterization for a list of animal radioligands.28–31 The protein series of the EDB piece is saved amongst the types, and the woodchucks’ EDB-FN is homologous to the human beings’.
Materials and Methods
Woodchuck Model of Naturally Occurring HCC
Three woodchucks (2 males: WC#1701 and WC#1741 and 1 female: WC#1857) of 8–10 pounds (balanced 3.5 kg) body weight were ultrasound-screened at Roswell Park Comprehensive Cancer Center (Buffalo, NY), picked and delivered to Case Western Reserve University (Cleveland, OH) when their liver blemishes were ≥20 millimeters determined along the long-axis. The vet at Roswell Park Cancer Center surgically implanted a venous gain access to port (SAI Infusion Technologies; Elgin, IL) in each animal prior to delivery to us in Cleveland to help with intravenous (i.v.) administration of the radiotracer for animal imaging. The port was flushed frequently with heparinized saline. The food was eliminated 4–5 hours prior to each animal imaging to help with the anesthesia treatment while drinking water was kept available. All treatments were authorized by the Institutional Animal Care and Use Committee (IACUC) of the University.
Bioinformatics
As reported formerly, TCGA information were downloaded from the general public TCGA Liver Hepatocellular Carcinoma database (TCGA-LIHC) and processed as formerly reported.32,33 The woodchuck information were gathered from the NCBI Gene Expression Omnibus (accession number GSE36545 and BioProject PRJNA155585). The information consist of 102 samples (GSM896624-GSM896725) from 13 woodchucks with an overall of 42 growth samples and 60 non-tumor samples.34 The information obtained were from a customized ActiveGen Woodchuck Gene Expression HX3 Microarray and formatted in parallel to the TCGA dataset, although the 2 sets of information were processed in a different way due to the distinction in the vibrant variety fundamental to each innovation.32,33
The expression of FN1 in between liver growths and non-tumor liver tissues was tallied from the databases. The human information originated from TCGA, and the woodchuck information from the tailored microarray. Homology of amino acid series in between human ([Homo sapiens]) and woodchuck ([marmot]) EDB-FN was figured out by utilizing Protein Basic Local Alignment Search Tool (BLAST) (https://blast.ncbi.nlm.nih.gov/Blast.cgi).
Synthesis of Radiolabeled ZD2-[68Ga-NOTA]
The radiosynthesis of ZD2-[68Ga-NOTA] was carried out in closed-system completely automated Scintomics GRP® synthesizer (Furstenfeldbruck, Germany) as reported formerly.8 Briefly, 68Ge/68Ga generator (design IGG-100) was utilized as a source of radionuclide. In the procedure of automated synthesis, 68Ga(III) was eluted from a generator with 0.1 M hydrochloric acid, and the eluent was watered down with water. The resulting option was travelled through the cationic exchange PS-H+ cartridge and consequently eluted with 5 M salt chloride option into a pre-heated reactor including ZD2-NOTA and HEPES buffer. The labeling was carried out in 10 minutes at 125°C. After response, the response material was moved onto C18 Plus Light SPE-cartridge, and the identified ZD2-(68Ga-NOTA) was eluted with a mix of water for injection/ethanol (1/1, v/v) through the 0.22 µm membrane sterilized filter into the end product vial. Finally, the item was watered down with a PBS buffer through the exact same sterilized 0.22 µm membrane filter into the end product vial. Samples are then aseptically eliminated for quality assurance screening.
FAMILY PET Imaging and Data Analysis
Woodchucks with a typical weight of 3.5 kg were too big to suit our microPET scanner and were positioned susceptible in our scientific Ingenuity PET/CT scanner (Philips, Cleveland, OH) rather. Under 3% isoflurane gas anesthesia, the animals had a low-dose CT scan initially, followed by i.v. injection of 37 ~ 56 MBq (1.0 ~ 1.5 mCi) ZD2-(68Ga-NOTA) through the implanted venous gain access to port. A vibrant animal acquisition in list mode began upon injection and lasted 60 minutes. The animal acquisition was re-binned into an overall of 21 frames: 10×30 seconds, 5 X 1-minutes, 2 X 5-min frames, and 4×10 min, respectively, and rebuilded utilizing iterative 3D-OSEM offered by the supplier including the integrated CT-based attenuation correction. After the scan, the animals were euthanized for tissue collecting consisting of growth and matched liver tissues. Some samples were fresh-frozen instantly for later usage in PCR or Western blot, while others were repaired with formaldehyde for histology.
Standardized Uptake Value (SUV, stabilized radiotracer uptake by body weight and injected tracer dosage)35 was computed for areas of interest (Return of investments) specified over focal uptakes of the ZD2 ligand in addition to a close-by ROI over the liver background far from focal uptakes, comparable to that utilized for calculating FDG uptake.36 Time activity curves in the system of SUV were created for these Return of investments.
EDB-FN Expression (PCR and Western Blot)
RNA was drawn out from formerly frozen tissue utilizing Qiagen miRNeasy Mini Kit (Qiagen) according to maker’s directions. The guides for qRT-PCR were created at The Custom TaqMan® Assay Design Tool based upon human mRNA series for necessary genes: EDB-FN (custom-made TaqMan gene expression assay AP47XKP), and endogenous control gene GAPDH (assay Hs02758991_g1). qRT-PCR was carried out on a StepOne Plus real-time thermocycler with 1.33 mL of cDNA for each response and the TaqMan Universal Master Mix II with UNG (Applied Biosystems). Expression information was processed likewise as in the past.32,33,37 The relative metrology of gene expression (RQ) for the recommendation sample was set as 1.
The exact same frozen liver tissues utilized for PCR above were defrosted and processed for Western blotting in a comparable style as prior to32,33,37 however with the main antibody particular to EDB-FN (G4, Abcam, Cambridge, MA). The blot was nurtured with an HRP-conjugated secondary antibody and after that treated with a chemiluminescent ECL reagent prior to advancement. ß-actin in the tissue specimens was utilized as a recommendation protein. The blots were cleaned in TBST and established with ECL Chemiluminescent detection reagent (Cytiva Amersham™). Chemiluminescence signals were imagined utilizing the direct exposure movie.
Histology
Fixed tissue samples embedded in the paraffin blocks were cut, and the histological areas were deparaffinized in xylene, ethanol, and faucet water cleans, and after that obstructed with 10% goat serum (Invitrogen, Carlsbad, CA) in PBS with 0.1% Tween 20 (PBS-T) (Gibco, Waltham, MA) for 30 minutes. The staining of the tissue slides was carried out with a business antibody particular to EDB-FN (G4, Abcam). In addition, the tissue slides were nurtured with ZD2-Cy5.5 (500 nM) in PBS-T for 1 hour. Following 3 washes with PBS-T, the areas were installed utilizing fluoroshield installing medium with DAPI (Abcam, Cambridge, UK). Images were obtained on a confocal microscopic lense utilizing pre-programmed emission and excitation filters for Cy5.5 (635 nm excitation, 693 nm emission) (Olympus, Tokyo, Japan) and DAPI (405 nm excitation, 461 nm emission).
Results
ZD2-[68Ga-NOTA]
The radioactive tracer ZD2-[68Ga-NOTA] was manufactured under the basic GMP conditions. The common decay-corrected radio-chemical yield (d.c. RCY) is ~71% (~54% n.d.c. RCY at EOS).
Quality control tests comparable to those for scientific formulas of [68Ga]Ga-identified peptides revealed that the item option was colorless without particles, pH = 7.0, endotoxin test <2 EU/mL, radiochemical pureness >90% as program by HPLC (C18 RP column, 0.1% TFA/H2O – 0.1% TFA/ACN). The typical particular activity was ~6 Ci/μmol. Stability research studies throughout 3 hours did not reveal any item destruction, and radiochemical pureness stayed the exact same on all test chromatograms.
Bioinformatics
The protein series of the EDB piece is saved in all mammalian types as validated by BLAST for the woodchucks whose EDB-FN series is 100% homology to the human beings, as displayed in Table 1. TCGA Liver Statistic revealed (http://cancergenome.nih.gov) a balanced RPKM (Reads Per Kilobase of records, per Million mapped checks out, a stabilized system for mRNA expression) of 8.7 for FN1 mRNA in liver cancer as compared to a balanced RPKM of 1.8 in liver parenchyma. High expression of EDB-FN in HCC is related to a drawback in client survival (https://portal.gdc.cancer.gov/projects/TCGA-LIHC), Figure 1. In contrast, the analysis of the tailored microarray information likewise revealed a greater EDB-FN expression in the woodchuck HCC comparing to the surrounding hepatic tissues (Figure 2A).
 |
Table 1 BLAST of EDB-FN Amino Acid Sequence Showing 100% Homology Between Human and Woodchuck |
 |
Figure 1 TCGA data showing higher EDB-FN expression in HCC compared with that in the liver (A), and the inverse correlation of EDB-FN expression in HCC with patient survival (B). |
 |
Figure 2 Validation results indicating highly expressed EDB-FN in the woodchuck HCC. (A) Higher EDB-FN expression in the woodchuck HCC compared to the surrounding hepatic tissues analyzed from the customized microarray data; Higher EDB-FN expression in HCC compared to the surrounding liver determined in harvested tissue samples from the woodchucks carrying HCC with RT-PCR (B) and Western blotting (C). |
PET Imaging of HCC with ZD2-[68Ga-NOTA]
PET imaging revealed a higher uptake of ZD2-[68Ga-NOTA] in woodchuck HCC than that in normal tissues and organs including liver, kidney, spleen, and muscle. Figure 3 reveals an excellent animal with HCC, which showed a high uptake in one HCC the in addition to a quick kidney clearance suggesting that the tracer was generally excreted through kidney filtering. The build-up of ZD2-[68Ga-NOTA] in HCC plateaued 10 minutes after injection and the liver background uptake supported 20 minutes post-injection. Animal pictures of other animals and the accompanying time activity curves for their Return of investments (Figures S1–S4) exist in the Supplemental Information.
 |
Figure 3 PET imaging of ZD2-[68Ga-NOTA] with woodchuck (#1701). (A) PET/CT overlays of coronal (left) and axial (right) cuts showing uptake in one HCC (T1 for tumor 1) with L for liver, S for stomach, and H for heart; (B) region-based uptake (in SUVs) as time activity curves for these organs. |
Histology
EDB-FN expression was also determined in the tumor sections using immunofluorescence staining with G4 anti-EDB-FN monoclonal antibody.38 As displayed in Figure 4A, significant expression of EDB-FN was observed in HCC, while no expression was observed in typical liver, constant with the reported lead to other cancers.39 The high expression of EDB-FN was generally observed in the extracellular matrix of the HCC.
 |
Figure 4 Histology analysis. (A) Immunofluorescence staining of woodchuck frozen sections (upper: liver, lower: tumor) with G4 anti-EDB-FN monoclonal antibody (red). While substantial EDB-FN was stained in the extracellular matrix of the HCC, normal liver was not stained; (B) Specific binding of ZD2 peptide to EDB-FN in woodchuck HCC was observed for strong binding of ZD2-Cy5.5 (red) in tumor tissues while little fluorescence staining was observed for the adjacent woodchuck HCC sections pre-incubated with G4 antibody and followed by ZD2-Cy5.5, indicating blockage of ZD2-Cy5.5 binding by G4 antibody (blocking). |
Specific binding of ZD2 peptide to EDB-FN in HCC was tested by incubating ZD2-Cy5.5 with the tumor sections. As shown in Figure 4B, strong binding of ZD2-Cy5.5 (red) was observed in growth tissues, comparable to the immunofluorescence staining in Figure 4A. Little fluorescence staining was observed for the HCC specimens pre-incubated with G4 antibody and followed by ZD2-Cy5.5, suggesting clog of ZD2-Cy5.5 binding by G4 antibody (stopping). The results recommend that both ZD2-Cy5.5 and G4 particularly bind to the exact same EDB-FN protein target in the growth tissues. Taken together, ZD2 peptide is an appealing targeting representative for particular binding of EDB-FN in HCC.
Expression of EDB-FN
The expression of EDB-FN was likewise figured out in collected tissue samples from the woodchucks bring HCC with RT-PCR (Figure 2B) and Western blotting (Figure 2C). The results show that EDB-FN is extremely revealed in the woodchuck HCC. In contrast, according to human Protein Atlas (https://www.proteinatlas.org/ENSG00000115414-FN1), FN1 gene mRNA expression is high in the lung, liver, and placenta tissues because order. However, protein levels are high in kidney and placenta, while moderate to low in other organs (cerebellum, adrenal glands, lungs, and so on.). The level of FN1 protein in the liver is low.
Discussion
Currently, basic radiological imaging (CT or MRI) supplemented with histopathological assessment following tissue biopsy is the pillar diagnostic method for the detection and medical diagnosis of HCC. These standard scientific imaging methods might be enhanced by utilizing animal imaging if an appropriate animal imaging biomarker exists. We have actually effectively analyzed a long list of little molecular animal radioligands with a medically appropriate animal design of HCC in woodchucks to verify the matching findings in a scientific setting concerning radiotracer uptake systems.28–31,40–46
EDB-FN (FN1), an oncofetal isoform of fibronectin, which is plentiful in ECM and perivascular space of growth microenvironment, is put together by stromal cells such as cancer-associated fibroblasts (CAFs, or tumor-associated fibroblasts: TAFs),47,48 connecting to high malignancy and poor diagnosis, while benign growths have little or no existence of the protein.19,22 As gone over listed below, among the cell surface area markers of these CAFs or TAFs utilized for targeting was the fibroblast triggered protein (FAP),49 which is not our target. Strong expression of EDB-FN in main growths is associated with a high occurrence of transition and poor general survival of clients identified with pancreatic, prostate, breast, ovarian, and head and neck cancer. TCGA (http://cancergenome.nih.gov) information showed that EDB-FN is likewise extremely revealed in HCC and is inversely associated with client survival (Figure 1).
Monoclonal antibodies have actually been established to particularly target EDB-FN in cancer. Imaging probes have actually been established and checked in kind utilizing some antibodies or their pieces such as L19 targeting EDB-FN.50,51 Because of their plus size and long flow time, a prolonged waiting time is needed for the clearance of unbound antibody-derived radiotracers from the flow and background for much better cancer imaging, which is not hassle-free for both the clients and clinicians. ZD2, a seven-amino acid peptide, was picked for radiolabeling and animal imaging in this job due to its high look frequency throughout phage screen and water solubility appropriate to be a family pet tracer, which are beneficial functions for decreasing non-specific tissue binding. The affinity was determined at 132 nM, which is in accord with the anticipated affinity to EDB-FN examined with AutoDock Vina.52 ZD2 did not bind to any cell surface area target(s), rather to the plentiful onco-fibronectin in the growth microenvironment. Due to this amplification, radiolabeled ZD2 with a modest binding affinity straight illustrated EDB-FN circulation related to the growth throughout animal imaging. This is various from the just recently established FAP inhibitor (FAPi)-based radioligands,53,54 which target the FAP on cell surface area of CAFs or TAFs. The ZD2 ligand was manufactured utilizing basic solid-phase peptide chemistry and chelated to 68Ga as a little molecular animal probe ZD2-(68Ga-NOTA) prior to imaging. The radiosynthesis was carried out with the existing GMP center for scientific Ga-68 tracers with a high yield and pureness. The peptide and ZD2-(68Ga-NOTA) are extremely water-soluble. The little size and water solubility enable fast diffusion of ZD2-(68Ga-NOTA) into growth tissues, thus successfully binding to EDB-FN in the growth ECM. Its high hydrophilicity would likewise lessen non-specific interactions with typical tissues, consisting of the liver, and enable fast clearance through kidney filtering for prompt and effective diagnostic imaging, as displayed in Figure 3.
Our long-lasting objective is to establish molecular animal imaging of EDB-FN, which has the prospective to offer non-invasive and precise medical diagnosis and risk-stratification of HCC to supplement basic scientific imaging such as ultrasound, contrast-enhanced multi-phase CT, and MR scans. This job began to identify EDB-FN expression in a medically appropriate animal design of HCC in woodchucks and carried out quantitative animal imaging analyses for examining the capacity of the EDB-FN-targeting peptide for future scientific translation. EDB-FN is extremely saved in between types (Table 1). Our initial animal imaging research studies utilizing this spontaneous woodchuck design of HCC plainly showed a high growth uptake of the EDB-FN-targeting peptide identified with 68Ga, while revealing a quick liver background washout. The animal design featured a level of hepatic fibrosis (which added to liver background uptake) causing the advancement of HCC however did not manifest to the degree of scientific cirrhosis. Conversely, cirrhosis is likewise missing in a sub-population of HCC clients with persistent HBV.55 The HCC in woodchucks is therefore important recapitulating the human HCC with comparable pathology and nature.27,56
Accurate decision of EDB-FN expression in growth microenvironment is vital for difference of aggressive HCC to help decision-making in client care. Furthermore, clients with liver cancer frequently bring other underlying liver or non-liver illness such as heart diseases, or digestion conditions, or neural-brain health problem. Identifying aggressive HCCs will help risk-stratification for focusing on general treatment strategies. Future efforts will be directed towards scientific translation to develop oncofetal protein EDB-FN as a brand-new target and ZD2-[68Ga-NOTA] as the matching radioligand for animal imaging of main liver cancers to supplement basic scientific scans and to minimize the requirement of liver biopsies.
Conclusion
Our results revealed that EDB-FN as an oncoprotein is a molecular target for delicate imaging of HCC. The ZD2 brief peptide radioligand targeting EDB-FN in liver cancer microenvironment appeared appropriate for animal imaging of HCC. This will possibly affect the scientific management of clients with HCC.
Acknowledgments
This research study was supported in part by National Institutes of Health (NIH) R01CA204373, R01CA211762, and R01CA235152, and by the Clinical and Translational Science Collaborative of Cleveland, UL1TR002548 from the National Center for Advancing Translational Sciences (NCATS) element of the NIH and NIH Roadmap for Medical Research. Its contents are entirely the duty of the authors and do not always represent the main views of the NIH. All speculative treatments were authorized by the Institutional Animal Care and Use Committee and Radiation Safety Committee at Case Western Reserve University (Cleveland, OH) and followed standards of United States Department of Agriculture Animal Welfare Act, Public Health Service Policy on Humane Care and Use of Laboratory Animals, and Association for Assessment and Accreditation of Laboratory Animal Care International.
Disclosure
Dr Songqi Gao reports a patent WO2020150617A8 certified to CWRU. Dr Zheng-Rong Lu reports a patent United States Patent App. 17/424,104 pending to Molecular Theranostics, LLC. The authors report no other disputes of interest in this work.
References
1. NIH. Action Plan for Liver Disease Research: A Report of the Liver Disease Subcommittee of the Digestive Diseases Interagency Coordinating Committee. NIH Publication; 2004.
2. Bruix J, Sherman M. Practice standards committee AAftSoLD. management of hepatocellular cancer. Hepatology. 2005;42(5):1208–1236. doi:10.1002/hep.20933
3. Lee JH, Lee JM, Kim SJ, et al. Enhancement patterns of hepatocellular cancers on multiphasic multidetector row CT: contrast with pathological distinction. Br J Radiol. 2012;85(1017):e573–e583. doi:10.1259/bjr/86767895
4. Jeng POUND, Changlai SP, Shen YY, Lin CC, Tsai CH, Kao CH. Limited worth of 18F-2-deoxyglucose positron emission tomography to spot hepatocellular cancer in liver disease B infection providers. Hepato-Gastroenterology. 2003;50(54):2154–2156.
5. Han Z, Zhou Z, Shi X, et al. EDB fibronectin particular peptide for prostate cancer targeting. Bioconjug Chem. 2015;26(5):830–838. doi:10.1021/acs.bioconjchem.5b00178
6. Han Z, Sergeeva O, Roelle S, et al. Preparation and assessment of ZD2 Peptide (64) Cu-DOTAConjugate as a positron emission tomography probe for detection and characterization of prostate cancer. A/C Omega. 2019;4(1):1185–1190.
7. Ayat NR, Vaidya A, Yeung GA, et al. Effective MR molecular imaging of triple unfavorable breast cancer with an EDB-fibronectin-specific contrast representative at decreased dosages. Front Oncol. 2019;9:1351.
8. Gao S, Qin J, Sergeeva O, et al. Synthesis and evaluation of ZD2-((68) Ga-NOTA)particular to extradomain B fibronectin in growth microenvironment for animal imaging of pancreatic cancer. Am J Nucl Med Mol Imaging. 2019;9(5):216–229.
9. Sauer S, Erba PA, Petrini M, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic growths makes it possible for ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma clients. Blood. 2009;113(10):2265–2274.
10. Wagner K, Schulz P, Scholz A, Wiedenmann B, Menrad A. The targeted immunocytokine L19-IL2 effectively hinders the development of orthotopic pancreatic cancer. Clin Cancer Res. 2008;14(15):4951–4960. doi:10.1158/1078-0432.CCR-08-0157
11. Antoon JW, Lai R, Struckhoff AP, et al. Altered death receptor signaling promotes epithelial-to-mesenchymal shift and obtained chemoresistance. Sci Rep. 2012;2:539. doi:10.1038/srep00539
12. Wang R, Cheng L, Xia J, Wang Z, Wu Q, Wang Z. Gemcitabine resistance is related to epithelial-mesenchymal shift and induction of HIF-1alpha in pancreatic cancer cells. Curr Cancer Drug Targets. 2014;14(4):407–417. doi:10.2174/1568009614666140226114015
13. Parvani JG, Gujrati MD, Mack MA, Schiemann WP, Lu ZR. Silencing beta3 integrin by targeted ECO/siRNA nanoparticles hinders emergency medical technician and transition of triple-negative breast cancer. Cancer Res. 2015;75(11):2316–2325. doi:10.1158/0008-5472.CAN-14-3485
14. Vaidya A, Wang H, Qian V, Gilmore H, Lu ZR. Overexpression of extradomain-B fibronectin is related to intrusion of breast cancer cells. Cells. 2020;9(8):1826.
15. Vaidya A, Ayat N, Buford M, et al. Noninvasive evaluation and restorative tracking of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin. Theranostics. 2020;10(24):11127–11143. doi:10.7150/thno.47448
16. Hesse E, Musholt PB, Potter E, et al. Oncofoetal fibronectin–a tumour-specific marker in finding very little recurring illness in distinguished thyroid cancer. Br J Cancer. 2005;93(5):565–570. doi:10.1038/sj.bjc.6602741
17. Kaspar M, Zardi L, Neri D. Fibronectin as target for growth treatment. Int J Cancer. 2006;118(6):1331–1339. doi:10.1002/ijc.21677
18. Mhawech P, Dulguerov P, Assaly M, Ares C, Allal AS. EB-D fibronectin expression in squamous cell cancer of the head and neck. Oral Oncol. 2005;41(1):82–88. doi:10.1016/j.oraloncology.2004.07.003
19. Richter P, Junker K, Franz M, et al. IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial cancer of the urinary bladder (UBC). J Cancer Res Clin Oncol. 2008;134(10):1059–1065. doi:10.1007/s00432-008-0390-6
20. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in clients with cancer. Clin Cancer Res. 2003;9(2):571–579.
21. Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L. Distribution of oncofetal fibronectin isoforms in typical, hyperplastic and neoplastic human breast tissues. Int J Cancer. 1994;59(1):11–16. doi:10.1002/ijc.2910590104
22. Nam JM, Onodera Y, Bissell MJ, Park CC. Breast cancer cells in three-dimensional culture show a boosted radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res. 2010;70(13):5238–5248. doi:10.1158/0008-5472.CAN-09-2319
23. Loridon-Rosa B, Vielh P, Matsuura H, Clausen H, Cuadrado C, Burtin P. Distribution of oncofetal fibronectin in human mammary growths: immunofluorescence research study on histological areas. Cancer Res. 1990;50(5):1608–1612.
24. Koukoulis GK, Howeedy AA, Korhonen M, Virtanen I, Gould VE. Distribution of tenascin, cellular fibronectins and integrins in the typical, hyperplastic and neoplastic breast. J Submicrosc Cytol Pathol. 1993;25(2):285–295.
25. Matsumoto E, Yoshida T, Kawarada Y, Sakakura T. Expression of fibronectin isoforms in human breast tissue: production of additional domain A+/additional domain B+ by cancer cells and additional domain A+ by stromal cells. Jpn J Cancer Res. 1999;90(3):320–325. doi:10.1111/j.1349-7006.1999.tb00750.x
26. Gould VE, Koukoulis GK, Virtanen I. Extracellular matrix proteins and their receptors in the typical, hyperplastic and neoplastic breast. Cell Differ Dev. 1990;32(3):409–416. doi:10.1016/0922-3371(90)90057-4
27. Korba BE, Wells FV, Baldwin B, et al. Hepatocellular cancer in woodchuck liver disease virus-infected woodchucks: existence of viral DNA in growth tissue from persistent providers and animals serologically recuperated from intense infections. Hepatology. 1989;9(3):461–470.
28. Midulla M, Verma R, Pignatelli M, Ritter MA, Courtenay-Luck NS, George AJ. Source of oncofetal ED-B-containing fibronectin: ramifications of production by both growth and endothelial cells. Cancer Res. 2000;60(1):164–169.
29. Salem N, Kuang Y, Wang F, Maclennan GT, Lee Z. animal imaging of hepatocellular cancer with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F] fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline. Q J Nucl Med Mol Imaging. 2009;53(2):144–156.
30. Kuang Y, Salem N, Tian H, et al. Imaging lipid synthesis in hepatocellular cancer with [methyl-11c]choline: connection with in vivo metabolic research studies. J Nucl Med. 2011;52(1):98–106. doi:10.2967/jnumed.110.080366
31. Salem N, Kuang Y, Corn D, et al. [(Methyl)1-(11)c]-acetate metabolic process in hepatocellular cancer. Mol Imaging Biol. 2011;13(1):140–151. doi:10.1007/s11307-010-0308-y
32. Kuang Y, Wang F, Corn DJ, Tian H, Lee Z. Metabolism of radiolabeled methionine in hepatocellular cancer. Mol Imaging Biol. 2014;16(1):44–52. doi:10.1007/s11307-013-0678-z
33. Kolthammer JA, Corn DJ, Tenley N, et al. Animal imaging of hepatocellular cancer with 18F-fluoroethylcholine and 11C-choline. Eur J Nucl Med Mol Imaging. 2011;38(7):1248–1256. doi:10.1007/s00259-011-1743-y
34. Kuang Y, Salem N, Corn DJ, et al. Transport and metabolic process of radiolabeled choline in hepatocellular cancer. Mol Pharm. 2010;7(6):2077–2092. doi:10.1021/mp1001922
35. Kuang Y, Salem N, Wang F, Schomisch SJ, Chandramouli V, Lee Z. A colorimetric assay approach to determine acetyl-CoA synthetase activity: application to woodchuck design of liver disease virus-induced hepatocellular cancer. J Biochem Biophys Methods. 2007;70(4):649–655. doi:10.1016/j.jbbm.2007.02.008
36. Kuang Y, Schomisch SJ, Chandramouli V, Lee Z. Hexokinase and glucose-6-phosphatase activity in woodchuck design of liver disease virus-induced hepatocellular cancer. Comp Biochem Physiol C Toxicol Pharmacol. 2006;143(2):225–231. doi:10.1016/j.cbpc.2006.02.005
37. Kuang Y, Wang F, Corn DJ, Tian H, Lee Z. In vitro characterization of uptake system of L-[methyl-(3)H]-methionine in hepatocellular cancer. Mol Imaging Biol. 2014;16(4):459–468. doi:10.1007/s11307-014-0720-9
38. Salem N, MacLennan GT, Kuang Y, et al. Quantitative assessment of 2-deoxy-2[F-18]fluoro-D-glucose-positron emission tomography imaging on the woodchuck design of hepatocellular cancer with histological connection. Mol Imaging Biol. 2007;9(3):135–143. doi:10.1007/s11307-007-0092-5
39. Andres Ibarra R, Abbas R, Kombu RS, et al. Disturbances in the glutathione/ophthalmate redox buffer system in the woodchuck design of liver disease virus-induced hepatocellular cancer. HPB Surg. 2011;2011:789323. doi:10.1155/2011/789323
40. Gerin JL, Cote PJ, Korba BE, Tennant BC. Hepadnavirus-caused liver cancer in woodchucks. Cancer Detect Prev. 1989;14(2):227–229.
41. Love MI, Huber W, Anders S. Moderated evaluation of fold modification and dispersion for RNA-seq information with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8
42. Fletcher SP, Chin DJ, Ji Y, et al. Transcriptomic analysis of the woodchuck design of persistent liver disease B. Hepatology. 2012;56(3):820–830. doi:10.1002/hep.25730
43. Han Z, Li Y, Roelle S, et al. Targeted contrast representative particular to an oncoprotein in growth microenvironment with the capacity for detection and threat stratification of prostate cancer with MRI. Bioconjug Chem. 2017;28(4):1031–1040. doi:10.1021/acs.bioconjchem.6b00719
44. Julyan PJ, Taylor JH, Hastings DL, Williams HA, Zweit J. SUVpeak: a brand-new specification for metrology of uptake in FDG FAMILY PET. Nucl Med Commun. 2004;25(4):407. doi:10.1097/00006231-200404000-00040
45. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: progressing Considerations for animal reaction requirements in strong growths. J Nucl Med. 2009;50(Suppl 1):122S–50S. doi:10.2967/jnumed.108.057307
46. Scarpino S, Stoppacciaro A, Pellegrini C, et al. Expression of EDA/EDB isoforms of fibronectin in papillary cancer of the thyroid. J Pathol. 1999;188(2):163–167. doi:10.1002/(SICI)1096-9896(199906)188:2<163::AID-PATH335>3.0.CO;2-1
47. Attieh Y, Clark AG, Grass C, et al. Cancer-associated fibroblasts lead growth intrusion through integrin-beta3-dependent fibronectin assembly. J Cell Biol. 2017;216(11):3509–3520. doi:10.1083/jcb.201702033
48. Erdogan B, Ao M, White LM, et al. Cancer-associated fibroblasts promote directional cancer cell migration by lining up fibronectin. J Cell Biol. 2017;216(11):3799–3816. doi:10.1083/jcb.201704053
49. Mhawech-Fauceglia P, Wang D, Samrao D, et al. Clinical ramifications of marker expression of carcinoma-associated fibroblasts (CAFs) in clients with epithelial ovarian cancer after treatment with neoadjuvant chemotherapy. Cancer Microenvir. 2014;7(1–2):33–39. doi:10.1007/s12307-013-0140-4
50. Conte GD, Tosi D, Fasolo A, et al. A Phase I trial of antifibronecitin 131I-L19-small immunoprotein (L19-SIP) in strong growths and lymphoproliferative illness. J Clin Oncol. 2008;26(15_suppl):2575. doi:10.1200/jco.2008.26.15_suppl.2575
51. Berndorff D, Borkowski S, Moosmayer D, et al. Imaging of growth angiogenesis utilizing 99mTc-labeled human recombinant anti-ED-B fibronectin antibody pieces. J Nucl Med. 2006;47(10):1707–1716.
52. Trott O, Olson AJ. AutoDock Vina: enhancing the speed and precision of docking with a brand-new scoring function, effective optimization, and multithreading. J Comput Chem. 2010;31(2):455–461. doi:10.1002/jcc.21334
53. Giesel FL, Kratochwil C, Lindner T, et al. (68)Ga-FAPI PET/CT: biodistribution and initial dosimetry quote of 2 DOTA-containing FAP-targeting representatives in clients with different cancers. J Nucl Med. 2019;60(3):386–392. doi:10.2967/jnumed.118.215913
54. Kratochwil C, Flechsig P, Lindner T, et al. (68)Ga-FAPI PET/CT: tracer uptake in 28 various sort of cancer. J Nucl Med. 2019;60(6):801–805. doi:10.2967/jnumed.119.227967
55. Chayanupatkul M, Omino R, Mittal S, et al. Hepatocellular cancer in the lack of cirrhosis in clients with persistent liver disease B virus infection. J Hepatol. 2017;66(2):355–362. doi:10.1016/j.jhep.2016.09.013
56. Tennant BC, Toshkov IA, Peek SF, et al. Hepatocellular cancer in the woodchuck design of liver disease B virus infection. Gastroenterology. 2004;127(5 Suppl 1):S283–S293. doi:10.1053/j.gastro.2004.09.043